FY2024 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright increased their FY2024 earnings estimates for shares of PolyPid in a note issued to investors on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($4.56) for the year, up from their previous estimate of ($4.83). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.79) EPS.

Separately, Craig Hallum started coverage on PolyPid in a research report on Monday, November 4th. They set a “buy” rating and a $10.00 target price on the stock.

PolyPid Trading Up 1.4 %

NASDAQ PYPD opened at $2.89 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $13.86 million, a P/E ratio of -0.37 and a beta of 1.33. PolyPid has a 52-week low of $2.37 and a 52-week high of $9.20. The firm has a 50-day moving average price of $3.24 and a 200 day moving average price of $3.51.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC bought a new position in shares of PolyPid Ltd. (NASDAQ:PYPD) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned approximately 2.89% of PolyPid as of its most recent filing with the Securities and Exchange Commission (SEC). 26.47% of the stock is owned by institutional investors and hedge funds.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.